MAP2K1
ENSG00000169032
Target class
Kinase
Chromosome
15
Approved drugs
7
Clinical candidates (approved and in development)
20
- Approved drugs
- 7
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 20
- Chemical probe available
- Yes
- Target name
- MAP2K1
- Gene name
- Mitogen-activated protein kinase kinase 1
- Gene symbol
- MAP2K1
- Previous gene symbols
- PRKMK1
- Protein name
- Dual specificity mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1) (MAPKK 1) (MKK1) (EC 2.7.12.2) (ERK activator kinase 1) (MAPK/ERK kinase 1) (MEK 1)
- MEK1
- MAPKK1
- MKK1
- Gene biotype
- Protein coding
- Gene family
- Mitogen-activated protein kinase kinases
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 99.13
- Tissue specificity (Gini)
- 0.237
- Tissue specificity (tau)
- 0.634
- KEGG gene identifiers
- hsa:5604
- Protein interaction confidence
- 0.8715
- Protein interaction partners
- 80
- R-HSA-110056
- R-HSA-170968
- R-HSA-445144
- R-HSA-5210891
- R-HSA-5673000
- R-HSA-5674135
- R-HSA-5674499
- R-HSA-5684264
- R-HSA-6802946
- R-HSA-6802948
- R-HSA-6802952
- R-HSA-6802955
- R-HSA-9649948
- R-HSA-9652169
- R-HSA-9656223
- End position
- 66491656
- Start position
- 66386825
- Chromosome
- 15
- Strand
- Forward
- Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, microtubule organizing center, spindle pole body . Cytoplasm . Nucleus . Membrane
- Peripheral membrane protein . Note=Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis (PubMed:14737111). Membrane localization is probably regulated by its interaction with KSR1 (PubMed:10409742). .
- Basal body
- Cytosol
- Plasma membrane
- PubMed 14737111
- PubMed 10409742
- PubMed 17101779
- Tissue specificity (tau)
- 0.634429
- Expression inequality (Gini)
- 0.237038
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 99.13
- Brain - Cerebellar Hemisphere
- 89.34
- Brain - Frontal Cortex (BA9)
- 87.08
- Brain - Nucleus accumbens (basal ganglia)
- 71.7
- Brain - Anterior cingulate cortex (BA24)
- 55.9
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes99.13
- Brain - Cerebellar Hemisphere89.34
- Brain - Frontal Cortex (BA9)87.08
- Brain - Nucleus accumbens (basal ganglia)71.7
- Brain - Anterior cingulate cortex (BA24)55.9
- Adipose - Subcutaneous53.17
- Brain - Cerebellum51.77
- Artery - Tibial51.39
- Artery - Aorta51.22
- Cells - Cultured fibroblasts47.69
- Esophagus - Mucosa44.26
- Brain - Caudate (basal ganglia)43.52
- Lung43.43
- Artery - Coronary42.42
- Brain - Hippocampus41.51
- Brain - Cortex41.44
- Nerve - Tibial41.3
- Muscle - Skeletal40.9
- Cervix - Ectocervix40.29
- Vagina39.98
- Adipose - Visceral (Omentum)39.35
- Uterus38.93
- Brain - Hypothalamus37.87
- Cervix - Endocervix36.83
- Brain - Amygdala36.63
And 29 more, listed on the interactive page.
- GO:0006935
- GO:0007165
- GO:0008285
- GO:0010628
- GO:0032872
- GO:0045893
- GO:0070371
- GO:0070374
- GO:0071902
- GO:0090170
- GO:0090398
- GO:2000641
- GO:0005634
- GO:0005737
- GO:0005739
- GO:0005769
- GO:0005770
- GO:0005783
- GO:0005794
- GO:0005829
- GO:0005886
- GO:0005925
- GO:0016020
- GO:0036064
- GO:0004672
- GO:0004674
- GO:0004708
- GO:0004712
- GO:0005078
- GO:0005515
- GO:0030295
- GO:0043539
- GO:0097110
Related records
Trials (1,104)
- "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma
- "Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"
- (Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma
- 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs
- 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
- 601 Versus Ranibizumab in Patients With Branch Retinal Vein Occlusion (BRVO)
- 601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
- A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris
- A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study Evaluating the Safety, Tolerability, and Efficacy of MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
- A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Single Intravenous Infusion of JWK007 in Patients With Duchenne Muscular Dystrophy (DMD)
- A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
- A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
- A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib
- A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism
- A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data
- A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
Drugs (20)
- AS-703988 Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Avutometinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- AZD-8330 Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Balamapimod Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Binimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- CI-1040 Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Cobimetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Cobimetinib fumarate Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- E-6201 Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Mirdametinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Pimasertib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Refametinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- RG-7167 Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
- RO-4987655 Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Selumetinib Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Selumetinib sulfate Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
- TAK-733 Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Trametinib Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
- Trametinib dimethyl sulfoxide Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- WX-554 Dual specificity mitogen-activated protein kinase kinase 1 inhibitor